Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Cardiology/Vascular Diseases
Disease Category: Peripheral Vascular Disease

Trial Information

Safety and Effectiveness Study of EverFlex Stent to Treat Symptomatic Femoral-Popliteal Atherosclerosis (DURABILITY II)

This is a multi-center, non-randomized, single arm study to compare PTA and primary stenting using a single PROTÉGÉ® EverFlex™ stent to performance goals of PTA alone in the treatment of atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions.

Patient Inclusion Criteria:

• Stenotic, restenotic (from PTA or adjunct therapy, not including stents or stent grafts) or occluded lesion(s) located in the native superficial femoral artery or superficial femoral and proximal popliteal arteries.
• Symptomatic femoral-popliteal atherosclerosis.
• Willing to comply with all follow-up evaluations at the specified times.
• Provides written informed consent prior to enrollment in the study.

Patient Exclusion Criteria:

• Previously implanted stent(s) or stent graft(s) in the target vessel.
• Planned use of devices other than angioplasty balloons during procedure.
• Received endovascular treatment of the target lesion (except stents/stent grafts) within six months of the index procedure.
• Life expectancy of less than 12 months.
• Symptomatic femoral disease in the opposite limb.

Kelly Colucci, Manager, Grants and Contracts
Atlantic Health System
475 South Street
Morristown, NJ 07962
Phone: 973-660-3139
EMail: kelly.colucci@atlantichealth.org

View Google Map

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.